MIR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MIR is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock is trading below its recent pivot and lacks a strong positive catalyst, while the short-term technical setup and pattern-based outlook are weak. Analyst sentiment remains positive overall, but the current price action and recent trend do not support an immediate buy. Best direct call: hold off for now.
Current price is 17.15, below the previous close of 17.38 and below the pivot level at 18.21. RSI_6 at 38.54 is neutral-to-weak, suggesting limited momentum. MACD histogram is slightly positive at 0.0363 but is contracting, which weakens the near-term bullish case. Moving averages are converging, indicating a lack of clear trend direction. Support sits near 17.20 and 16.58, while resistance is at 19.22 and 19.84. The pattern-based forecast is bearish, with a projected -2.21% next day, -3.07% next week, and -4.33% next month.
Options positioning is strongly call-skewed, which indicates underlying bullish sentiment. No negative news was reported in the last week, so there is no fresh event-driven pressure from headlines.
No news in the recent week means there is no immediate catalyst to push the stock higher. The price is weak on the day, down 2.96% in regular trading and 1.32% post-market. The stock sits below key technical reference levels, and the pattern-based trend forecast is negative across the next day, week, and month. Hedge funds and insiders are neutral, so there is no supportive buying signal from smart money. No recent congress or influential figure trading data was available.
No usable financial snapshot was available due to a data error, so latest-quarter revenue and earnings growth cannot be assessed from the provided data. As a result, there is no confirmed fundamental acceleration to support a long-term buy decision from this dataset.
Wall Street remains favorable overall: Evercore ISI, Citi, and Goldman Sachs all maintained positive ratings (Outperform or Buy) while lowering price targets modestly from $29 to $28. This suggests pros still see upside potential, but the recent target cuts show slightly less enthusiasm than before. The analyst view is bullish in rating but somewhat cautious in target adjustments.
